Construction of 124 I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients

ConclusionThe findings described here demonstrated that124I-trastuzumab was feasible to detect HER2-positive lesions in primary and metastatic gastric cancer patients and to differentiate HER2-positive and HER2-negative lesions quantitatively.Graphic abstract
Source: Gastric Cancer - Category: Gastroenterology Source Type: research